This paper examines the strengths and limitations of these imaging modalities through the assessment of sensitivity and resolution trade-offs as defined by modality, isotope (or fluorophore) selection, labeling method and dosimetry. A description of the basic principles behind the imaging techniques is provided along with a discussion of labeling methods relevant to antibodies with a focus on the role of modality and isotope selection on study design and execution. Image and select analysis results from a case study are presented with a discussion of output data content and relevant informatics gained in such studies.
IMAGING PHYSICS
SPECT and PET are nuclear medicine imaging techniques used to measure the threedimensional distribution of a radiopharmaceutical administered to a patient or subject. In both SPECT and PET, the decay of a radioactive probe conjugated to the antibody of interest results in detectable signals outside the patient or subject. Specifically, projection data are generated through the estimation of the location and energy of high-energy photons interacting with a detector material, typically via the photoelectric effect in high-density crystals or electron-hole pair production in semi-conductors (Wagner et al., 1968; Barrett and Myers, 2004; Wernick and Aarsvold, 2004; Barrett, 2005) . The three-dimensional spatial distribution of the injected radionuclide is estimated through reconstruction of the projection data into an image, either by a filtered backprojection or a statistical-based iterative algorithm (Gullberg, 1979; Shepp and Vardi, 1982; Feldkamp et al., 1984; Lange and Carson, 1984; Kaufman, 1987; Fessler et al., 1991; Hudson and Larkin, 1994) . In other words, the three-dimensional image created from a SPECT or PET scan maps the radionuclide-antibody conjugate within the patient or subject.
SPECT
As the acronym implies, SPECT cameras image individual high-energy photons (gamma rays or characteristic x-rays) resulting from radionuclide decays. These single-photon emissions follow a 4S-geometry, i.e. radiate outward in all directions with equal probability. Therefore, an aperture comprised of highly attenuating material is required to identify the path of origin of each emission prior to creation of an image with a gamma camera (Copeland and Benjamin, This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 11, 2011 as DOI: 10.1124 at ASPET Journals on January 15, 2018 jpet.aspetjournals.org
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1949; Anger, 1952; Anger, 1967) . The two most common aperture or 'gamma-ray collimator' types are parallel-hole and pinhole collimators. The former is used most often in the clinic while the latter is used when the field of view (FOV) of the patient or subject is small with respect to the size of the detector FOV, e.g. a human thyroid or a mouse. The volumetric resolution of pinhole SPECT imaging systems is a function of the magnification and diameter of the pinhole aperture as well as the intrinsic resolution of the gamma camera (Jaszczak et al., 1994; Fessler, 1998; Bequé et al., 2003; Schramm et al., 2003; Accorsi and Metzler, 2004; Beekman and Vastenhouw, 2004; Furenlid et al., 2004; Meikle et al., 2004; Aoi et al., 2006; Funk et al., 2006; Acton and Kung, 2003) .
PET
In contrast to SPECT, wherein the radionuclide emits a detectable photon, PET imaging utilizes a radionuclide that emits a positron, also known as the anti-matter of an electron. The positron travels some distance (typically on the order of a millimeter) before encountering an electron, transiently combining and annihilating. The annihilation produces two photons of identical energy (511 keV) traveling in nearly opposite directions (i.e. ~180° apart), a process referred to as coincidence. The identification of this coincident photon pair is executed by a ring of crystal detectors (typically lutetium yttrium orthosilicate or bismuth germinate) coupled to photomultiplier or photodiode detectors. The localization of this photon pair enables the estimation of the origin of the annihilation and thus, radionuclide distribution within the subject without the need for a high-density, attenuating aperture. The ability in PET to image without the use of gamma collimators or apertures results in a higher sensitivity of PET as compared to SPECT instrumentation. The volumetric resolution of PET imaging systems is a function of positron range prior to annihilation (proportional to the energy of the positron emission), detector geometry and intrinsic resolution, and the temporal resolution of the gamma detection process (Cherry et al., 1997; Jeavons et al., 1998; Chatziioannou et al., 1999; Cherry, 2006; Phelps, 2009 ).
Physical characteristics of SPECT and PET isotopes
This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 11, 2011 as DOI: 10.1124 A primary physical property for consideration of any isotope used in an imaging study is its radioactive half-life. In practice, the half-life of the isotope selected should be at a minimum 2-fold longer than the biological half-life of the event kinetics to be imaged (Gambhir, 2002) .
Due to relatively long-lived circulation, imaging antibody pharmacokinetics can be a challenge.
The maximum possible duration of an imaging study depends on the effective half life of the labeled antibody:
where T E is the effective half-life of the radiolabeled antibody, T B is the biological half-life of the antibody and T I is the physical half-life of the isotope. In practice, given typical injected doses and acquisition times, small-animal SPECT and PET systems are able to image out to about four effective half-lives. For example, an antibody with a 72 hour biological half-life labeled with 111 In (67.2 hour physical half-life) has an effective half-life of 34.7 hours permitting imaging out to approximately six days. The differences between the half-lives of SPECT and PET isotopes are significant with the oft-preferred longer-lived half-lives belonging to SPECT.
An exception to this is 124 I for PET, with a 4.2 day half-life ( scintillation detectors (Weber et al., 1994; Beekman et al., 2002; Accorsi and Metzler, 2004; Lackas, 2005; Beekman and Have, 2007) . For PET isotopes, reconstructed resolution depends primarily on two factors: the positron range (i.e., the distance traveled by a positron prior to annihilation with an electron) and photon non-colinearity (the deviation from 180° in the emitted photon paths caused by residual momentum of the electron-hole pair at annihilation) (Chatziioannou, 1999) . Because this paper is concerned with small-animal scanners, it is primarily the disparity in positron range that is responsible for the large variation in reconstructed resolution for the isotopes shown in Table 2 .
In the clinical setting, PET resolution tends to exceed SPECT resolution for numerous reasons associated with the need for SPECT imaging apertures. For example, in clinical SPECT imaging, because the patient size and associated FOV are on the order of the size of the available detectors, parallel-hole collimators are used for most applications. The degradation in spatial resolution and sensitivity attributable to these collimators exceeds the similar detrimental effects of the physical limitations associated with PET imaging, resulting in higher spatial resolutions in PET. However, the opposite is true in preclinical imaging in small-animal models. The effects of the aforementioned positron range and the difficulty in accurately estimating the interaction location of the relatively higher energy photons associated with PET isotopes are more pronounced due to the smaller subject volumes (Levin and Hoffman, 1999) . Conversely, these small imaging volumes enable the use of high magnification apertures in SPECT imaging, increasing sensitivity and resolution relative to their clinical counterparts (Schramm et al., 2003; Beekman et al., 2005) .
Nuclear medicine imaging physics follows Poisson statistics, as the nature of radioactive decay is that of an independent counting event. That the mean equals the variance for a Poisson random variable translates into reduced noise and improved estimation of the radioisotope distribution as the number of detected photons increases. Achieving the physical limits of reconstructed resolution also depends strongly on the number of acquired counts. In both PET and SPECT, the number of acquired counts is dictated by the geometric efficiency and resolution settings of the system (how many photons emitting from the field of view are collected by the system) and the physical properties of the isotopes used in the study (Wilson and Tsui, 1993; Barrett et al., 1994; Wilson et al., 1994; Kupinski et al., 2003; Barrett and Myers, 2004; Barrett, 2005) . Differences in sensitivity between isotopes are governed primarily by the number of sensitivity is strongly correlated with positron intensity. Further, the absence of an aperture in PET imaging results in higher system (i.e., isotope-independent) sensitivity compared to SPECT imaging. System geometry also dictates the sensitivity response of a system over the volume of a subject. In both PET and SPECT, the system sensitivity decreases significantly, e.g. 30-70%, between the center of the field of view and the edge of the field of view (Beekman et al., 2002; Schramm et al., 2003; Chatziioannou, 2005; Cherry, 2006) .
The relationship between sensitivity and imaging volume as a function of isotope is presented in Tables 1 and 2 microSPECT (the NanoSPECT/CT, Bioscan, USA). The average sensitivities were calculated using a ray-tracing technique (Schramm et al., 2003) and validated with 99m
Tc and 111 In. In direct comparison, microPET imaging is ~3-4 times more sensitive than microSPECT imaging at similar reconstructed resolution (~4 mm 3 , achieved with a 2 mm-diameter pinhole array in SPECT). Through pinhole-diameter reduction from 2 mm to 1 mm, reconstructed resolution is improved eight-fold (from ~4 mm 3 to ~0.5 mm 3 ). This gain in resolution, however, is accompanied by a four-fold loss in sensitivity.
Given that nuclear medicine imaging involves the administration of radioactive probes, it is also necessary to consider the radiation dose to the subject. As defined above, the unit of cps/µCi/cc provides a measure of expected counting statistics as a function of the amount of radioactivity injected and the animal mass. The amount and type of isotope as well as the effective half-life of the radiolabeled antibody determines the absorbed dose (expressed in units of gray, Gy) received by the mouse from the administered radiolabeled agent (Funk et al., 2004; Hindorf et al., 2004) . The absorbed dose to the animal is a function of the cumulated activity (µCi·s) and the mean dose per unit cumulated activity (Gy/µCi·s) or S-value (Weber, 1990; Stabin and Siegel, 2003) . Dose values are provided for each isotope in Tables 1 and 2 Estimating the effects of low radiation doses over an extended period of time in mice is difficult to fully characterize. There has been significant investigation into the effect of radiation dose from multiple microCT studies or [ 18 F]-fluorodeoxyglucose PET with absorbed dose values equivalent to the studies described here (Daibes et al., 2004; Laforest et al., 2004; Taschereau and Chatziioannou, 2007) . For reference, the whole-body lethal dose to 50% of mice in a cohort within 30 days (LD(50/30)) is on the order of 6 Gy when generated with a single (<10 minute) exposure to radiation (Prosser et al., 1947; Samarth and Kumar, 2003) and tumor eradication doses in xenograft tumor models are on the order of 50 Gy (Govindan et al., 2000) . In practice, the absorbed doses for a typical 111 In-or 125 I-labeled antibody study are equivalent to longitudinal multi-dose [ 18 F]-fluorodeoxyglucose studies with 4-6 timepoints with microCT image collection (approximately 0.5-2.5 Gy over the course of a couple of weeks). There does not exist a consensus in the literature as to the impact of absorbed dose in such studies (Carlson et al., 2007 Iodination is typically performed using one of two methods, direct labeling in the presence of an oxidizing agent or indirect labeling with an intermediate iodinated compound (Hermanson, 1996) . Direct labeling methods are the more common of the two and oxidizing agents used in solution or immobilized to solid supports are available commercially (Pierce).
Immobilized oxidizing agent and enzymatic iodination via lactoperoxidase result in a slower and more controllable iodination process. Direct iodination results in the modification of tyrosine phenolic groups and histidine imidazole groups. Indirect iodination methods allow conjugation to other functional groups such as primary amines and have been described (Hermanson, 1996) . As with bifunctional metal chelates, iodination results in a heterogeneous mixture of radiolabeled protein with radioiodine incorporated at various locations. Low levels of iodination via the direct labeling method does not typically affect protein activity, due to the relatively small size of iodine, unless the active site contains a large number of surface accessible tyrosine and/or histidine residues (Kung et al., 2000) . Site-specific iodination has been described (Arano et al., 1994 ).
99m
Tc 99m Tc can be incorporated into proteins using direct and indirect labeling methods (Banerjee et al., 2001) . In direct labeling, disulfide bonds are reduced under mild conditions and the 99m
Tc is coordinated to the sulfhydryls. Indirect labeling is typically preferred due to improved stability (Hnatowich et al., 1993) and is performed using bifunctional metal chelates such as mercaptoacetyltriglycine (MAG3) (Winnard et al., 1997) , Sacetylmercaptoacetyltriglycine (Chang et al., 1999) , or hydrazinonicotinamide (Babich et al., 1993) , or can be accomplished through the incorporation into the protein a hexahistidine peptide (Waibel et al., 1999) . The latter approach is only used with proteins produced recombinantly, and will result in site specific modification. NHS derivatives of hydrazinonicotinamide are available commercially (Solulink). NHS derivatives of MAG3 and S-acetylmercaptoacetyltriglycine can be prepared in-house (Winnard et al., 1997; Chang et al., 1999; Misra et al., 2007 ) and conjugated to proteins in a straightforward manner under mildly basic conditions. Conjugation results in a heterogenous mixture of chelate modified proteins as in the other methods discussed above.
A variety of methods to label proteins with 18 F have been described (Guhlke et al., 1994; Cai et al., 2008; McBride et al., 2010) , however labeling with this particular isotope generally remains a challenge due to its short half-life, low radiochemical yields, and low specific Radioisotope incorporation for all approaches described above can be determined by thin layer chromatography or size-exclusion chromatography. It is generally good practice to evaluate the modified protein for its biological activity by in vitro assays specific to the particular application. Also, protein and label stability can be assessed by incubation in serum and analysis by appropriate methods such as size-exclusion chromatography to determine extent of degradation.
The selection of an appropriate isotope for imaging antibody pharmacokinetics depends on a variety of factors including 1) antibody blood clearance half-life, 2) imaging time points desired and study design, and 3) antibody dose (low doses will require high specific activity and/or high gamma abundance to achieve high quality images). As outlined in Tables 1 and 2, the physical properties of different isotopes are important in study design given their significant influence on sensitivity and reconstructed resolution as well as the temporal window of measurement allotted by their radioactive half-life. Compromises are inevitable.
Isotope selection
In vivo activity is associated with the biodistribution of the isotope, a signal that is not exclusively correlated with the biodistribution of the full-length protein of interest. Thus it is important to take into consideration the stability and in vivo behavior of the isotope conjugation.
For example, enzymes in the blood will slowly dehalogenate iodinated compounds and the dissociated iodine will result in increased uptake in the thyroid and lower uptake in the blood and other organs.
Antibody internalized by cells will undergo degradation by proteases in endosomes and lysosomes. Directly iodinated compounds generally result in relatively low cellular iodine retention (Press et al., 1996) . Indirect iodination using residualizing labels has been reported to Tc-MAG3 labels also exit the cell more slowly (Engfeldt et al., 2007) while chelated metal cations exhibit even slower cellular release with a half-life of ~120 h (Press et al., 1996) . These residualization kinetics must be taken into account when analyzing data as they can have a large impact on the apparent biodistribution especially at longer time points. Similarly, for tumor targeting antibodies, tumor activity levels will not accurately represent the concentration of intact antibody in the tumor as the total activity will be a sum of extracellular-localized (radiolabel associated with free and surface-bound antibody) and intracellular-localized isotope (Shih et al., 1994; Ferl et al., 2006) .
OPTICAL IMAGING
Optical imaging relies on the detection of photons in the visible to near-infrared portion of the electromagnetic spectrum produced by bioluminescence or fluorescence (Weissleder, 2002) . Bioluminescence is a chemical process wherein light is emitted during the interaction of a protein produced in engineered cells and an administered substrate, for example firefly luciferase and luciferin (de Wet et al., 1987) . Fluorescence imaging utilizes probes that emit light (fluoresce) following the excitation at a fluorophore-specific wavelength. The subsequent emission of light is shifted to a longer wavelength by an amount known as the Stokes shift. For example, widely-used green fluorescent protein, mutated to improve fluorescence and photostability by Helm and colleagues, has a primary excitation peak at 489 nm and primary emission peak at 509 nm (Helm et al., 1995) .
The pharmacokinetics of fluorophore-labeled antibodies can be assessed with fluorescence imaging, however, determination of antibody localization is limited by the absorption properties of tissues. Developments in fluorophore chemistries have result in a series of fluorochromes with emissions extending from the ultraviolet through the visible spectrum and into the near-infrared (Weissleder et al., 1999; Weissleder and Mahmood, 2001 ). The latter is advantageous since tissue absorption of signal and auto fluorescence is minimized at these wavelengths. But even in the near-infrared range, organs at depth remain difficult to detect.
Three-dimensional image reconstruction of fluorophores has been demonstrated in both academic and commercial environments, however results with this modality are almost exclusively two-dimensional. Generally, only organs/areas of interest on or near the surface will be detected reliably (Arridge, 1999; Ntziachristos and Weissleder, 2001; Ntziachristos et al., 2002; Grimm et al., 2005; Ntziachristos et al., 2005; Morimoto, 2007; Weissleder and Pittet, 2008) . 
EXAMPLE DATA
Results from an experiment comparing the kinetics of two different 111 In-labeled antibodies (specific and non-specific) in a xenograft tumor model are presented in Figure 1 .
SPECT and CT images (NanoSPECT/CT, Bioscan Inc., Washington DC) were collected at 3, 24, 48, 72 and 96 hours post injection. Whole-body helical SPECT studies using 36 pinholes (1.4mm diameter) were collected with 16 minute acquisition times at hour 3, scaling up to 24 minute acquisition times at hour 96 ( Figure 1A ). Whole-body helical CT studies were collected with acquisition times of 3 minutes at a tube setting of 45 kVp (average x-ray energy of just under 45 keV). Antibodies were conjugated with DTPA followed by radiolabeling with 111 In.
Each animal received an intravenous injection of 111 In-labeled antibody (600 µCi, 15 µg) in 100 µL sterile saline.
At each time point for each animal in the study (in this case 16 animals were imaged daily) region-of-interest analysis was performed on each of the following organs: tumor, brain, spleen, heart, liver, kidneys, bladder, muscle and whole body through a combination of manual, semi-and fully automated segmentation routines. An example of a sub-organ analysis technique possible with small-animal nuclear imaging is presented in Figure 1B . Longitudinal radial profiles of tumors provide a means of assessing changes in distribution and concentration as well as a means to visualize the heterogeneity of antibody distribution within the tumor.
Both microSPECT and microPET systems provide images in units of radioactivity per volume. A broad range of output data are available with these nuclear techniques including activity (µCi or kBq), activity per volume (µCi/mm 3 or kBq/mm 3 ), standardized uptake value (SUV), a measure of ROI activity per volume normalized by the injected dose per subject mass (i.e. 'whole-body' concentration), percent injected dose, percent injected dose per gram and concentration (nM) when the specific activity of the radiolabeled antibody is available.
Typically, ex vivo biodistribution analyses are performed following collection of the final image.
Extensive work has been performed assessing the precision of the quantification in these techniques as well as correlating in vivo and ex vivo results (Forrer et al., 2006; Rolleman et al., 2008) .
DISCUSSION
Advances in pre-clinical imaging instrumentation and analysis methods have created the means for assessing antibody pharmacokinetics in vivo. This review has focused on a basic description of the imaging modalities and labeling methods used in these studies with a focus on the role of modality and isotope selection in study design. While some of the information provided from such studies is attainable with in vitro and ex vivo techniques, opportunity to measure organ and sub-organ antibody kinetics longitudinally in a mouse resides exclusively with the molecular imaging approaches outlined in this review. SPECT and PET offer radiolabeled antibody imaging resolution and sensitivity that translates from mouse to human.
The cost of laboratory instrumentation and infrastructure for these modalities is significant though labeling and imaging facilities are widely available. Designing and executing such studies is a multi-disciplinary effort encompassing physics, mathematics, biology, pharmacology, engineering, and chemistry. Ultimately, the selection of a labeling method and imaging modality must be made expertly and with sound understanding of the complex factors governing signal origin, detection, and contamination.
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TABLES
(a) Volumetric reconstructed resolution is determined via theoretical and experimental assessment using a commercial microSPECT system (NanoSPECT/CT, Bioscan, Inc) and a hot-rod phantom.
This article has not been copyedited and formatted. The final version may differ from this version. . Sensitivity values are provided for two system geometries: the first row assumes a 1 mm pinhole geometry (corresponding to the displayed reconstructed resolutions) while the second row assumes a 2.0 mm pinhole geometry (corresponding to PET-like reconstructed resolutions).
(c) Dose values are provided in terms of the whole-body absorbed dose assuming a 100 µCi injected dose and either 72 hour biological half-life or infinite biological half-life (i.e., no biological clearance, dose is limited only by isotope half-life).
(d) The radioisotope-to-antibody ratio is calculated from reported specific activity measurements of radiolabeled antibodies and antibody fragments and the theoretical specific activity of the isotope.
(e) A single "+" is on the order of $1/mCi while "+++++" is on the order of $100/mCi. Note that costs will vary according to location and institution.
(f) DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DTPA, diethylenetriaminepentaacetic acid; HYNAC, hydrazinonicotinamide; MAG3, mercaptoacetyltriglycine;
This article has not been copyedited and formatted. The final version may differ from this version. Physical properties include isotope half-life, mean annihilation distance in mm, positron abundance, volumetric reconstructed resolution, sensitivity, dose properties, and specific activity. Radiochemical properties include the radioisotope-to-antibody ratio and primary labeling method. Primary strengths and limitations and relative costs for each isotope are also provided.
(a) Volumetric reconstructed resolution is computed by convolving the mean annihilation distance with an optimal 3hr 24hr 48hr 72hr 96hr
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